H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $120 and keeps a Buy rating on the shares post the Q4 report. The firm says the company has a solid commercial outlook. The analyst modulated the firm’s peak market share expectations for Vykat in the U.S. to 20% of the total Prader-Willi syndrome market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
- Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo
- Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability
- Soleno Therapeutics price target lowered to $85 from $120 at TD Cowen
- Soleno Therapeutics CFO Mackaness to retire, Fulk to succeed